Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Urinary Bladder Neoplasms 26Non-Muscle Invasive Bladder Neoplasms 11Colorectal Neoplasms 3Colonic Neoplasms 3Recurrence 2Neoplasms 2Melanoma 2Lung Neoplasms 2Side Effect of Drug 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Osteosarcoma 1Oligospermia 1Neuroblastoma 1Fibrosis 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melanoma × BCG Vaccine × Clear all
NCT01838200 2022-10-12

Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

Ludwig Institute for Cancer Research

Phase 1 Terminated
5 enrolled 12 charts
Dermatologic

Melanoma

NCT00003715 2015-12-03

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

AVAX Technologies

Phase 2 Terminated
425 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡